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A B S T R A C T
Background
Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive
arterial disease. However, the role of prophylaxis in individuals with abdominal aortic aneurysm (AAA) remains unclear. Several studies
have shown that despite successful repair, those people with AAA have a poorer rate of survival than healthy controls. People with AAA
have an increased prevalence of coronary heart disease and risk of cardiovascular events. Despite this association, little is known about
the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA. This is an update of a Cochrane
review ﬁrst published in 2014.
Objectives
To determine the long-term effectiveness of antiplatelet, antihypertensive or lipid-lowering medication in reducing mortality and
cardiovascular events in people with abdominal aortic aneurysm (AAA).
Search methods
For this update the Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register (14 April
2016). In addition, the CIS searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 3) and trials
registries (14 April 2016) and We also searched the reference lists of relevant articles.
Selection criteria
Randomised controlled trials in which people with AAA were randomly allocated to one prophylactic treatment versus another, a
different regimen of the same treatment, a placebo, or no treatment were eligible for inclusion in this review. Primary outcomes included
all-cause mortality and cardiovascular mortality.
Data collection and analysis
Two review authors independently selected studies for inclusion, and completed quality assessment and data extraction. We resolved
any disagreements by discussion. Only one study met the inclusion criteria of the review, therefore we were unable to perform meta-
analysis.
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Main results
No new studies met the inclusion criteria for this update. We included one randomised controlled trial in the review. A subgroup of
227 participants with AAA received either metoprolol (N = 111) or placebo (N = 116). There was no clear evidence that metoprolol
reduced all-cause mortality (odds ratio (OR) 0.17, 95% conﬁdence interval (CI) 0.02 to 1.41), cardiovascular death (OR 0.20, 95%
CI 0.02 to 1.76), AAA-related death (OR 1.05, 95% CI 0.06 to 16.92) or increased nonfatal cardiovascular events (OR 1.44, 95%
CI 0.58 to 3.57) 30 days postoperatively. Furthermore, at six months postoperatively, estimated effects were compatible with beneﬁt
and harm for all-cause mortality (OR 0.71, 95% CI 0.26 to 1.95), cardiovascular death (OR 0.73, 95% CI 0.23 to 2.39) and nonfatal
cardiovascular events (OR 1.41, 95% CI 0.59 to 3.35). Adverse drug effects were reported for the whole study population and were
not available for the subgroup of participants with AAA. We considered the study to be at a generally low risk of bias. We downgraded
the quality of the evidence for all outcomes to low. We downgraded the quality of evidence for imprecision as only one study with a
small number of participants was available, the number of events was small and the result was consistent with beneﬁt and harm.
Authors’ conclusions
Due to the limited number of included trials, there is insufﬁcient evidence to draw any conclusions about the effectiveness of cardio-
vascular prophylaxis in reducing mortality and cardiovascular events in people with AAA. Further good-quality randomised controlled
trials that examine many types of prophylaxis with long-term follow-up are required before ﬁrm conclusions can be made.
P L A I N L A N G U A G E S U M M A R Y
Medical treatment of vascular risk factors for reducing death and cardiovascular events in peoplewith abdominal aortic aneurysm
Background
Abdominal aortic aneurysm (AAA) is a potentially life-threatening condition where the aorta enlarges and can ultimately burst, leading
to massive internal bleeding. Current guidelines recommend that AAAs of 55 mm or more should be surgically repaired because, at
this size, the risk of rupture outweighs the risk of surgical repair. AAAs between 30 mm and 54 mm in size are not as high risk and
are generally monitored by regular scans to check for further enlargement. Recent research has shown that even after the aneurysm is
repaired, the survival rate in people with AAA is poorer than in people without AAA. In most cases, the cause of death is a cardiovascular
event, such as a heart attack or a stroke. Conditions such as high blood pressure or high cholesterol increase the risk of cardiovascular
death. However, both conditions can be reversed through medical treatment. Given the increased risk of mortality with AAA, it is
important to determine which medical treatment is most effective in preventing cardiovascular death in people with AAA.
In this review, researchers from Cochrane examined the effectiveness of medical treatment to treat vascular risk factors and reduce
deaths and cardiovascular deaths and events in people with an AAA.
Study characteristics and key results
After searching for all relevant studies (until 14 April 2016), we found one study in which a subgroup of 227 people with AAA received
either the beta-blocker metoprolol (medication that reduces blood pressure) or a placebo (dummy treatment). This study’s results were
imprecise for all causes of death and death from cardiovascular disease or nonfatal cardiovascular events at 30 days or six months
after AAA repair. Side effects from the drug were reported for the whole study population and were not available for the subgroup of
participants with AAA.
Quality of the evidence
We judged this study to be at a generally low risk of bias. We graded the quality of the evidence to low as we only included one small
sized study in the review, there were few events reported and the result was consistent with beneﬁt and harm.
Larger and longer studies are needed to ﬁnd out which treatment is most effective. At present, people with AAA are offered a wide
range of pharmacological treatment including antiplatelet drugs, antihypertensives and lipid-lowering drugs. Future trials should test
available drugs to ﬁnd the most effective strategy, whether that be one single drug or a combination of treatments. In addition, the
acceptability of such interventions needs to be assessed and future studies should measure adverse side effects associated with these
drugs and their impact on quality of life.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Metoprolol compared to placebo for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm (AAA)
Patient or population: pat ients of any age with AAA less than 30 mm in diameter
Setting: hospital
Intervention: metoprolol
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with metoprolol
All-cause mortality, 30
days1
Study populat ion OR 0.17
(0.02 to 1.41)
227
(1 RCT)
⊕⊕©©
low2
-
52 per 1000 9 per 1000
(1 to 71)
Cardiovascular death,
30 days3
Study populat ion OR 0.20
(0.02 to 1.76)
227
(1 RCT)
⊕⊕©©
low2
-
43 per 1000 9 per 1000
(1 to 73)
AAA-related death, 30
days4
Study populat ion OR 1.05
(0.06 to 16.92)
227
(1 RCT)
⊕⊕©©
low2
-
9 per 1000 9 per 1000
(1 to 128)
Nonfatal cardiovascu-
lar event, 30 days5
Study populat ion OR 1.44
(0.58 to 3.57)
227
(1 RCT)
⊕⊕©©
low2
-
78 per 1000 108 per 1000
(47 to 231)
All-cause mortality, 6
months1
Study populat ion OR 0.71
(0.26 to 1.95)
227
(1 RCT)
⊕⊕©©
low2
-
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86 per 1000 63 per 1000
(24 to 155)
Cardiovascular death, 6
months3
Study populat ion OR 0.73
(0.23 to 2.39)
227
(1 RCT)
⊕⊕©©
low2
-
60 per 1000 45 per 1000
(15 to 133)
AAA-related death, 6
months4
See comments See comments See comments See comments The incidence of AAA-
related death was not
measured at six months
Nonfatal cardiovascu-
lar event, 6 months5
Study populat ion OR 1.41
(0.59 to 3.35)
227
(1 RCT)
⊕⊕©©
low2
-
86 per 1000 117 per 1000
(53 to 240)
* The risk with placebo was the average risk in the placebo group (i.e. the number of part icipants with events divided by total number of part icipants of the placebo group
included in the meta-analysis). The risk in the metoprolol group (and its 95% CI) is based on the assumed risk in the placebo group and the relat ive ef fect of the intervent ion
(and its 95%CI).
Abbreviations: AAA: abdominal aort ic aneurysm; CI: conf idence interval; MI: myocardial infarct ion; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Death f rom all causes.
2Quality of evidence downgraded to low for imprecision due to low number of events, small sample size and wide CIs.
3Fatal MI, fatal stroke and other vascular deaths.
4Death due to abdominal aort ic aneurysm.
5Nonfatal MI, nonfatal stroke, or transient ischaemic attack.
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B A C K G R O U N D
Description of the condition
An abdominal aortic aneurysm (AAA) is an abnormal dilatation
of the aorta as it passes below the renal arteries to the point of bi-
furcation, where it forms the left and right common iliac arteries.
The clinical deﬁnition of AAA varies, although a maximum in-
frarenalmeasurement (ameasurement taken below the renal artery
branches) of ≥ 30 mm is commonly used (Wanhainen 2008).
The prevalence of AAA is six times greater in men than in women
(Pleumeekers 1995), with one study demonstrating a prevalence
of 1.3% in women and 7.6% in men (Scott 2002). Apart from
male gender, other risk factors for AAA include smoking, increased
age, and family history of AAA (Blanchard 2000). Conclusive ev-
idence from several studies has shown smoking to be associated
with AAA (Badger 2009; Greenhalgh 2008; Wilmink 1999). One
study,Wilmink 1999, estimated that the risk of AAA is seven times
higher in smokers and three times higher in ex-smokers compared
with age-matched nonsmokers, and another study reported that
90% of participants with AAA were smokers (Greenhalgh 2008).
Increased age has been consistently shown as a signiﬁcant risk fac-
tor (Lloyd 2010; Singh 2001). One population-based study of
6386 men and women reported no AAA in participants younger
than 48 years of age, but from this age onward the prevalence
increased linearly in both men and women (Singh 2001). Family
history is another known risk factor for AAA. One study reported
that 9% to 12% of ﬁrst-degree relatives of a participant with an
AAA will develop an aneurysm (van Vlijmen-van Keulen 2002).
The decision to operate on an AAA is made when the risk of rup-
ture is greater than the risk associated with the operation, and bur-
den of co-morbidity is increasingly important (Ohrlander 2011).
The UK Small Aneurysm Trial estimated that the annual rupture
rate is 0.3% for AAAs that are less than 4 cm in diameter, 1.5%
for 4.0 cm to 4.9 cm AAAs, and 6.5% for 5.0 cm to 5.9 cm AAAs
(Brown 1999). In general, the AmericanHeart Association and the
UK Aneurysm Screening Programme recommend that patients
with infrarenal AAAs measuring ≥ 55 mm should undergo repair
to eliminate the risk of rupture (Hirsch 2005). AAAs can be re-
paired using an open or endovascular approach. Open repair with
graft placement is a major procedure and may be preferred when
patients are ﬁt because complications are fewer and patients do
not routinely require follow-up. Endograft repair involving stent
placement (EVAR) is associated with a lower postoperative risk
and is therefore considered when the patient is a high surgical risk
or has coexisting medical conditions. The major risks in repairing
an AAA are perioperative cardiac events, infection, and death. The
30-day mortality has been estimated at 5% in elective open sur-
gical AAA repair compared with 1.7% with EVAR (Greenhalgh
2004; Prinssen 2004). However, a recent study showed no signif-
icant difference in survival at ﬁve years in participants who had
undergone open repair compared with EVAR (Brown 2011). Pa-
tients with an infrarenal AAA of 30 mm to 54 mm are moni-
tored by ultrasound or computed tomography (CT) scans every
three, six, or 12 months for detection of possible expansion and
the need for repair. These patients are considered for statin ther-
apy to reduce vascular risk, decrease the risk of rupture and reduce
aneurysm growth rates (Davis 2008). Angiotensin-converting en-
zyme (ACE) inhibitors and angiotensin receptor blockers have also
been proposed to reduce aneurysmal growth (Hackam 2006).
Studies have shown that even after successful surgical repair of an
AAA, participants had a poorer survival rate than healthy controls
(de Bruin 2014; De Martino 2013; Timmers 2013). A Dutch co-
hort study measured a survival rate of 59% 10 years after open
AAA repair, and patients had a poorer health-related quality of
life than age-matched controls (Timmers 2013). Another Dutch
study compared statin use in patients undergoing AAA repair and
found that while statins were associated with fewer cardiovascular
deaths, several risk factors remained that were associated with poor
survival after AAA repair including age of greater than 70 years,
a history of cardiac disease, and moderate to severe tobacco use
(de Bruin 2014). A further study of 2637 participants undergoing
AAA repair determined that although ﬁve-year survival rates were
similar between open and EVAR repair groups, advanced age ≥
75 years, coronary artery disease, unstable angina or recent my-
ocardial infarction (MI), oxygen-dependent chronic obstructive
pulmonary disease, and an estimated glomerular ﬁltration rate of
less than 30 mL/min/1.73 m2 were associated with poor survival
at ﬁve years (De Martino 2013).
A recent study conducted in Australia demonstrated an association
between AAA thrombus volume and subsequent cardiovascular
events (Parr 2011). AAA thrombus products are released into the
circulation where they have the potential to stimulate leukocytes
and produce other changes that might promote atherosclerotic
plaque activation and acute coronary and cerebrovascular events
(Morange 2006; Parry 2009; Smith 2005; Takagi 2009).
AAA size and growth are associatedwith local generationof inﬂam-
mation markers such as interleukin-6, matrix metalliproteinase-
2 (MMP-2), and MMP-9 (Schouten 2006). Inﬂammation also
seems to be important in perioperative adverse cardiac events.
Larger AAA size is independently associated with an increased in-
cidence of perioperative cardiovascular complications after elective
infrarenal AAA repair (Schouten 2006).
Description of the intervention
Pharmacological therapy to reduce cardiovascular risk factors such
as hypertension and hypercholesterolaemia. Examples of pharma-
cological therapy are antiplatelet therapy (e.g. aspirin, clopido-
grel, ticlopidine, cilostazol, or any other antiplatelet drugs), an-
tihypertensive drugs (e.g. calcium channel blockers, angiotensin-
converting enzyme (ACE) inhibitors, beta-blockers (β-blockers),
or any other antihypertensive drugs) and lipid-lowering therapy
(e.g. statins).
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How the intervention might work
As people with AAA have increased cardiovascular risks, pharma-
cological therapy may reduce cardiovascular mortality and nonfa-
tal cardiovascular events.
Why it is important to do this review
Three Cochrane systematic reviews on the effectiveness of sur-
gical treatment of AAA have been conducted. Badger 2014 and
Paravastu 2014 both compared endovascular versus open surgi-
cal repair for AAA, while Filardo 2015 examined immediate re-
pair versus routine ultrasound surveillance. Another published
Cochrane review, Rughani 2012, examined the effectiveness of
medical treatments in terms of the expansion rate of small ab-
dominal aortic aneurysms. However, these reviews have focused
on treatment of AAA and ruptured AAA rather than on treatment
of vascular risk factors associated with cardiovascular mortality in
participants with AAA.
Acquired risk factors such as hypertension and hypercholes-
terolaemia are often reversible through pharmacological therapy.
Given the increased risk of mortality with AAA, it is important
to determine which prophylaxis is most effective in preventing
cardiovascular death in people with AAA. To date, no systematic
review has been conducted to study the effectiveness of medical
treatments in reducing cardiovascular mortality in people with
AAA. This review sought to provide evidence on themost effective
medical treatment for this important problem.
This is an update of a Cochrane review ﬁrst published in 2014.
O B J E C T I V E S
To determine the long-term effectiveness of antiplatelet, antihy-
pertensive or lipid-lowering medication in reducing mortality and
cardiovascular events in people with abdominal aortic aneurysm
(AAA).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials in which participants with abdom-
inal aortic aneurysm (AAA) were randomly allocated to one pro-
phylactic treatment versus another, a different regimen of the same
treatment, a placebo, or no treatment.We planned to include pub-
lished studies and studies in progress, if preliminary results were
available. Non-English studies were eligible and we sought trans-
lations, where appropriate, for inclusion in the review.
Types of participants
Men and women of any age with AAA of less than 30 mm in di-
ameter as measured by standardised techniques such as ultrasound
examination or CT.We also included participants who had under-
gone endovascular or open surgical repair for AAA. In participants
who had an AAA repair, the time period included in this review
was the postoperative rather than the surveillance phase. We only
included mixed population studies where data on the subset of
participants with AAA were available.
Types of interventions
• Antiplatelet therapy (e.g. aspirin, clopidogrel, ticlopidine,
cilostazol, or any other antiplatelet drugs).
• Antihypertensive drugs (e.g. calcium channel blockers,
angiotensin-converting enzyme (ACE) inhibitors, beta-blockers
(β-blockers), or any other antihypertensive drugs).
• Lipid-lowering therapy (e.g. statins).
• Combination treatment (e.g. antiplatelet drug plus
antihypertensive or statin) versus single treatment.
• Combination treatment versus no treatment.
Where possible, we planned to compare one intervention with
another treatment, a different regimen of the same treatment,
placebo, or no treatment. We included any type, method, dura-
tion, timing, mode of delivery, and dose of medical treatment.
We excluded studies in which participants were not treated with a
speciﬁc regimen but were given numerous medications as it would
not be possible to attribute outcomes or side effects to one partic-
ular regimen.
This review concerns medical interventions in which the principal
actions are to modify cardiovascular risk factors. Therefore, we
did not include any alternative treatments for which the primary
purpose was to treat the aneurysm itself, for example to reduce
growth rates or prevent rupture, or both.
Types of outcome measures
Primary outcomes
• All-cause mortality.
• Cardiovascular mortality (fatal myocardial infarction (MI),
fatal stroke, other vascular deaths).
Secondary outcomes
• AAA-related death.
• Nonfatal cardiovascular events (nonfatal MI, nonfatal
stroke, or transient ischaemic attack).
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• Major amputation.
• Quality of life.
• Drug-related morbidity.
• Drug-related mortality.
We excluded outcomes that were speciﬁc to the aneurysm itself
(for example, change in size or rupture rates).
Search methods for identification of studies
We sought translations of any trials that were not in the English
language.
Electronic searches
For this update the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials.
• The Cochrane Vascular Specialised Register (14 April
2016).
• The Cochrane Central Register of Controlled Trials
(CENTRAL (2016, Issue 3)) via the Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy the CIS used to
search CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINEOvid, EmbaseOvid, CINAHL, AMED, and through hand-
searching relevant journals. The full list of the databases, journals
and conference proceedings which have been searched, as well as
the search strategies used, are described in the Specialised Register
section of the Cochrane Vascular module in the Cochrane Library
(www.cochranelibrary.com).
The CIS searched the following trial databases for details of ongo-
ing and unpublished studies using the terms abdominal aneurysm
(14 April 2016):
• World Health Organization International Clinical Trials
Registry Platform (http://apps.who.int/trialsearch/).
• ClinicalTrials.gov (http://clinicaltrials.gov/).
• ISRCTN Register (www.isrctn.com/).
See Appendix 2 for details of the search strategies.
Searching other resources
We reviewed the reference lists of relevant studies.
Data collection and analysis
Selection of studies
One review author (LR) used the selection criteria to identify trials
for inclusion and assessed the titles and abstracts of all identiﬁed
studies for relevance and design. The second review author (EA)
independently conﬁrmed this selection, and we resolved any dis-
agreements through discussion. We obtained the full-text articles
of any potentially relevant studies. Two review authors indepen-
dently assessed the full-text articles.We resolved any disagreements
by discussion. We listed all studies excluded after full-text assess-
ment in a ’Characteristics of excluded studies’ table. We planned
to include any studies that were published in duplicate only once
in the review. We constructed a PRISMA diagram to illustrate the
study selection process.
Data extraction and management
Two review authors (LR, EA) independently extracted the data.
We recorded information about the trial design; AAA deﬁnition
andmeasurementmethods; baseline characteristics of participants;
treatment type, method, duration, timing, mode of delivery, and
dose. We reported all-cause mortality and cardiovascular mortal-
ity data as the primary outcome measures. Also, we collected in-
formation on non-cardiovascular events and adverse events in ac-
cordance with the secondary outcome measures. We planned to
contact the study authors for further information if we required
clariﬁcation.We resolved any disagreements in data extraction and
management by discussion.
Assessment of risk of bias in included studies
Two review authors (LR, EA) independently used the Cochrane
’Risk of bias’ assessment tool, Higgins 2011, to assess the risk
of bias in the included study). This tool provides a protocol for
judgements on sequence generation, allocationmethods, blinding,
incomplete outcome data, selective outcome reporting, and any
other relevant biases.We resolved any disagreements by discussion.
Measures of treatment effect
Weplanned to base the analysis on intention-to-treat data from the
individual clinical trials. As the primary and secondary outcomes
are all binary measures, we computed odds ratios (ORs) using a
ﬁxed-effect model. We calculated the 95% conﬁdence intervals
(CIs) of the effect sizes.
Unit of analysis issues
The unit of analysis was the individual participant. However, as
the trial involved repeat measurements on participants at different
points in time, it was prone to unit of analysis errors (Deeks 2011).
Therefore, for the purpose of this review, we chose cardiovascular
mortality at ﬁve years as the primary endpoint. We planned to
include outcomes at longer follow-up periods as secondary out-
comes if reported.
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Dealing with missing data
We sought information about dropouts, withdrawals, and other
missing data. If not reported, we attempted to contact the study
authors.
Assessment of heterogeneity
The inclusion of studies on a wide range of medical treatments
was likely to result in a high degree of heterogeneity. We therefore
planned to assess the heterogeneity between pooled studies by
using the Chi2 test regarding the characteristics and quality of
included studies (Deeks 2011).
We planned to perform the Chi2 test to assess heterogeneity in
identiﬁed subgroups, and we planned to use the I2 statistic to
measure the degree of inconsistency between studies. An I2 statistic
result of greater than 50% may represent moderate to substantial
heterogeneity (Deeks 2011). Only one study met the inclusion
criteria for the review and therefore it was not necessary tomeasure
the heterogeneity between studies.
Assessment of reporting biases
Weplanned to assess reporting biases such as publication bias using
funnel plots (Sterne 2011). As only one study met the inclusion
criteria of this review, which was at a low risk of reporting bias, we
did not perform this.
Data synthesis
Two review authors (LR, EA) independently extracted the data.
One review author (LR) entered the data into Review Manager
5 (RevMan 5) (RevMan 2014). The second review author (EA)
cross-checked data entry, and we resolved any discrepancies by
consulting the source publication.
We used a ﬁxed-effect model to meta-analyse the data.
Subgroup analysis and investigation of heterogeneity
Where possible, we planned to analyse clinically relevant sub-
groups based on drug and participant groupings including the fol-
lowing.
• Diameter of aneurysm.
• Type of repair (e.g. endovascular versus surgical).
• Type of repair (e.g. endovascular or surgical) versus no
repair.
• Diabetes.
• Year of publication.
However, as only one studywith 227participantsmet the inclusion
criteria, it was not possible to perform subgroup analyses.
Sensitivity analysis
We planned to conduct a sensitivity analysis by excluding studies
at a high risk of bias to measure the effect on the results. However,
as there was only one included study we were unable to conduct
a sensitivity analysis.
’Summary of findings’ table
We presented the main ﬁndings of the review results concerning
the quality of evidence, the magnitude of effect of the interven-
tions examined, and the sum of available data for all-cause mortal-
ity, cardiovascular mortality, AAA-related death, and nonfatal car-
diovascular events in a ’Summary of ﬁndings’ table, according to
the GRADE principles as described by Higgins 2011 and Atkins
2004. We used the GRADEproﬁler Guideline Development Tool
(GRADEpro GDT) software to assist in the preparation of the
’Summary of ﬁndings’ table (GRADEpro GDT 2014).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
See the ’Characteristics of included studies’ table.
No new studies met the inclusion criteria for this update.
The review includes one study (Yang 2006). Yang 2006 is a dou-
ble-blind, randomised, placebo-controlled trial that measured the
effects of metoprolol on the incidence of cardiac complications at
30 days and six months after vascular surgery. The study included
496 participants who underwent procedures including abdominal
aortic repair and infrainguinal or axillofemoral revascularisation.
A subgroup of 227 participant had an abdominal aortic repair.
Although the trial authors did not present outcome data for the
abdominal aortic aneurysm (AAA) subgroup in the full report,
we obtained these data through personal communication with the
study author and statistician. Of the 227 AAA participants, 111
were randomised to metoprolol and 116 were randomised to a
placebo. The doses of metoprolol were as follows: 100 mg in par-
ticipants weighing ≥ 75 kg, 50 mg for participants weighing be-
tween 40 mg and 75 kg, and 25 mg for those weighing ≤ 40 kg.
Beta-blocker therapy was commenced preoperatively on the day of
surgery and continued for the duration of the hospital stay.Within
two hours postsurgery, the study drug was administered orally or
intravenously for 15 minutes (metoprolol 1 mg/mL or saline at
0.2 mL/kg, diluted with 20 mL of saline). Study medication was
continued intravenously every six hours or orally twice a day for
ﬁve days or until hospital discharge, whichever occurred sooner.
Intravenous study drug was converted to oral as soon as the par-
ticipant tolerated oral intake. The trial performed 30-day and six-
month follow-ups by telephone for discharged participants. Yang
2006 deﬁned the primary outcome as a composite of cardiac com-
plications at 30 days postoperation including: cardiac death, non-
fatal myocardial infarction (MI), congestive heart failure (CHF),
unstable angina, and dysrhythmia requiring treatment, deﬁned
as atrial ﬁbrillation or ventricular dysrhythmias. In the presence
of more than one outcome, the ﬁrst outcome was recorded. Sec-
ondary study outcomes included study drug discontinuation (due
to bronchospasm, hypotension, or bradycardia), amputation, and
intraoperative hypotension or bradycardia.
Excluded studies
See the ’Characteristics of excluded studies’ table.
For this update we excluded seven completed studies (Ashes 2013;
Berwanger 2015; Kouvelos 2011; Qu 2014; Schouten 2011; Xia
2014; Xia 2015), and one ongoing study (NCT01225094).
In total, we excluded 17 studies from the review (Ashes 2013;
Berwanger 2015; Cesanek 2008; DECREASE Study; Durazzo
2004; Kouvelos 2011; Kouvelos 2013; Mackey 2006; Mangano
1996; NCT01225094; Neilipovitz 2012; POBBLE Trial; POISE
Study; Qu 2014; Schouten 2011; Xia 2014; Xia 2015). Two stud-
ies, Durazzo 2004 and POBBLE Trial, had AAA subgroups but
did not present speciﬁc outcome data for these participant. The
author of one study, Durazzo 2004, conﬁrmed through personal
communication that these data were not available.We were unable
to contact the authors of the POBBLE Trial. Ten studies did not
report AAA subgroups (Ashes 2013; Berwanger 2015; Cesanek
2008; Kouvelos 2011; Mangano 1996; POISE Study; Qu 2014;
Schouten 2011; Xia 2014; Xia 2015). Authors of the POISEStudy
conﬁrmed that outcome data for AAA participants were not avail-
able, but the other nine study authors did not respond (Ashes
2013; Berwanger 2015; Cesanek 2008; Kouvelos 2011; Mangano
1996; Qu 2014; Schouten 2011; Xia 2014; Xia 2015). One study,
Mackey 2006, was not a randomised controlled trial but a prospec-
tive study that measured the incidence of myocardial injury in vas-
cular surgery patients. In two studies participants were taking co-
medications and therefore we could not attribute the results to one
particular drug (Kouvelos 2013; Neilipovitz 2012). We excluded
the DECREASE Study as the integrity of the data was question-
able. In a report released by Erasmus MC Follow-Up Committee
in 2012, the principal investigator admitted that written informed
consent was not obtained for every participant and that the data
were collected in a negligent manner (Erasmus MC Follow-Up
Committee 2012). Finally, one ongoing study tested the effects of
curcumin, a natural health product (NCT01225094).
Risk of bias in included studies
See the ’Risk of bias’ table in the ’Characteristics of included
studies’ section, and Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
Allocation
A study statistician performed random sequence generation in
blocks of four and therefore we judged the study to be at a low
risk of selection bias. However, the study authors did not report
the methods used to conceal allocation of treatment and therefore
the risk of selection bias was unclear.
Blinding
All study participants, investigators, caretakers and data outcome
evaluators of Yang 2006 were blinded to treatment. Furthermore,
blinding was maintained throughout the study, even if study med-
ication was discontinued.
Incomplete outcome data
The two treatment groups in Yang 2006 were well-balanced with
respect to baseline characteristics, completion of the study pro-
tocol, and discontinuation of treatment. Furthermore, the study
authors accounted for and reported on all missing data.
Selective reporting
The authors of Yang 2006 speciﬁed their hypothesis using results
from previously published work. They clearly stated their primary
and secondary outcomes and reported data on all outcomes.
Other potential sources of bias
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We considered the Yang 2006 study to be at low risk of other
potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparisonMetoprolol
compared to placebo for reducing mortality and cardiovascular
events in patients with abdominal aortic aneurysm
As only one study, Yang 2006, met the inclusion criteria, we were
unable to pool data or perform a meta-analysis. Therefore, we
reported the individual estimates from the study in a narrative
synthesis. The included study did not measure mortality at ﬁve
years but at two shorter time points of 30 days and six months
postoperation. Results indicated no clear evidence that metoprolol
reduced all-cause or cardiovascular mortality at 30 days: the inci-
dence of all-cause mortality was 1/111 in the metoprolol group
and 6/116 in the placebo group (odds ratio (OR) 0.17, 95% conﬁ-
dence interval (CI) 0.02 to 1.41) while the incidence of cardiovas-
cular mortality at 30 days was 1/111 and 5/116 in the metoprolol
and placebo groups respectively (OR 0.20, 95% CI 0.02 to 1.76).
One participant in each treatment group died of causes related to
AAA (OR 1.05, 95% CI 0.06 to 16.92). Nonfatal cardiovascular
events occurred in 12/111 in the metoprolol group and 9/116 in
the placebo group at 30 days (OR 1.44, 95% CI 0.58 to 3.57). At
six months, metoprolol did not signiﬁcantly reduce the rate of all-
cause mortality (OR 0.71, 95% CI 0.26 to 1.95) or cardiovascular
deaths (OR 0.73, 95% CI 0.23 to 2.39). The incidence of AAA-
related death was not measured at six months. The incidence of
nonfatal cardiovascular events was similar between the two treat-
ment groups at six months (OR 1.41, 95% CI 0.59 to 3.35). For
these outcomes, we downgraded the quality of the evidence to low.
The quality of evidence was downgraded due to imprecision, as
only one study with a small number of participants met the in-
clusion criteria, the number of events was low, and the result was
consistent with beneﬁt and harm. No participant had to undergo
an amputation. Quality of life was not reported.
Yang 2006 reported on adverse events in the form of study drug
discontinuation (due to bronchospasm, hypotension, or bradycar-
dia) and intraoperative hypotension or bradycardia. However, data
on study drug discontinuation and the incidence of intraoperative
hypotension or bradycardia were not available for the subgroup
of AAA participants. In the overall study of 496 participants, the
study authors reported that the incidence of intraoperative com-
plications was signiﬁcantly higher in the metoprolol group (P <
0.01). Hypotension occurred in 54% of metoprolol participants
(46% required treatment) compared to 41% of placebo partic-
ipants (34% required treatment). Bradycardia occurred in 35%
and 10% of metoprolol and placebo participants, respectively, of
whom 22% and 7% required treatment. However, given that these
outcomes are based on a population of participants who had un-
dergone vascular surgery for other conditions, we cannot gener-
alise the results to participants with AAA.
D I S C U S S I O N
Summary of main results
Only one study fulﬁlled the inclusion criteria of this review. The
study was a randomised controlled trial in which 496 participants
undergoing non-cardiac vascular surgery received either metopro-
lol or placebo (Yang 2006).We received data on a subgroup of 227
participants who underwent AAA repair from the study author.
Results of the study indicate that metoprolol is not associated with
a reduction in the rate of all-cause or cardiovascular mortality at
either 30 days or six months. No participant had to undergo an
amputation. Quality of life was not reported. Adverse drug effects
were reported for the whole study population and were not avail-
able for the subgroup of participants with AAA. We downgraded
the quality of the evidence due to imprecision, as only one study
with a small number of participants met the inclusion criteria,
the number of events was low, and the result was consistent with
beneﬁt and harm.
Overall completeness and applicability of
evidence
Currently, there is a severe lack of evidence concerning the effec-
tiveness of pharmacological prophylaxis in the prevention of car-
diovascular events in AAA patients. The one included study was
relatively small and tested one beta-blocker against a placebo at 30
days and six months follow-up. Therefore, the results of this study
are not widely applicable to the AAA population and the follow-
up period was relatively short to study mortality and cardiovas-
cular events in such participants. Recent evidence has questioned
whether beta-blockers are of any perioperative value and suggests
they may be harmful (Bolsin 2013). As there are many different
drugs available, it is important to test these drugs, not just against
a placebo but also against each other. Furthermore, it is important
to establish if a combination of drugs would yield a better outcome
than one drug alone.
Quality of the evidence
The quality of reporting in the single included study was good.
With the exception of failing to report themethods used to conceal
allocation of treatments, the study authors provided adequate in-
formation on the process of randomisation and blinding. As such,
we deemed the study to be at a low risk of selection, performance,
and detection bias. Additionally, the study authors accounted for
all missing data and reported data on all primary and secondary
outcomes, and therefore minimised the chances of attrition and
performance bias. For all outcomes, we downgraded the quality
of the evidence to low. We downgraded the quality of evidence
for imprecision, as there was only one included study with a small
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number of participants, the number of events was small, and the
conﬁdence intervals (CI) indicated both beneﬁt and harm.
Potential biases in the review process
We, the authors of this Cochane review, were neither involved in
the included study nor in any of the excluded studies. Furthermore,
we do not have any commercial or other conﬂict of interest. The
search was as comprehensive as possible and two review authors
independently assessed all studies for inclusion. We are conﬁdent
that we have included all relevant studies and attempted to reduce
bias in the review process. However, the possibility remains that
we may have missed studies that have not been published.
Agreements and disagreements with other
studies or reviews
This is an update of a Cochrane review ﬁrst published in 2014 and
the ﬁrst systematic review to measure the effectiveness of phar-
macological prophylaxis in reducing cardiovascular morbidity and
mortality in AAA patients. One prospective study of AAA partici-
pants who were followed up over amedian of 4.7 years determined
that, in those who survived AAA repair, beta-blocker use was as-
sociated with a signiﬁcantly lower incidence of all-cause mortal-
ity (hazard ratio (HR) 0.6, 95% CI 0.5 to 0.9) and cardiovascu-
lar mortality (HR 0.7, 95% CI 0.4 to 0.9) (Kertai 2004). After
adjusting for clinical risk factors and beta-blocker use, the same
study showed that long-term use of statins showed a reduction in
both all-cause and cardiovascular mortality (HR 0.4, 95% CI 0.3
to 0.6; and HR 0.3, 95% CI 0.2 to 0.6 respectively). Therefore,
it would appear that statins reduce cardiovascular risk regardless
of beta-blocker use. However, this was a prospective cohort study
with no randomisation and therefore likely to be at high risk of
bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the one study that met the inclusion criteria of this
Cochrane review, there is insufﬁcient evidence to draw any con-
clusions about the effectiveness of cardiovascular prophylaxis in
reducing mortality and cardiovascular events in people with AAA.
Although the study was of low risk of bias, we downgraded the
quality of the evidence for imprecision, as only one study with a
small number of participants was available, the number of events
was small, and the result was consistent with beneﬁt and harm.
Further good-quality randomised controlled trials are required.
There are awide range of prophylactic treatments for AAApatients
that need to be tested for effectiveness and other outcomes, such as
adverse side effects and quality of life. They also need to be tested
at long-term endpoints, such as ﬁve years or greater. The introduc-
tion of AAA screening programmes in the UK has provided a valu-
able tool to identify patients with AAA and therefore potentially
modify risk factors in those at high cardiovascular risk. However,
until adequate evidence regarding the efﬁcacy and acceptability of
interventions is available, deﬁnitive conclusions cannot be made.
Implications for research
The results of this systematic review conﬁrm the need for large
randomised controlled trials with longer follow-up (ﬁve years or
greater) to determine the effectiveness of pharmacological prophy-
laxis in preventing mortality and cardiovascular events in AAA
patients. At present, patients with AAA are offered a wide range
of pharmacological prophylaxes including antiplatelet drugs, an-
tihypertensives, and lipid-lowering drugs. Future research should
test the available drugs to ﬁnd the most effective strategy, whether
that be one drug alone or a combination of treatments. Moreover,
the acceptability of such interventions needs to be assessed. Thus,
any future studies should also analyse the secondary effects of such
interventions, including adverse side effects and quality of life.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Yang 2006
Methods Study type: double-blind randomised controlled trial
Study aim: to test the hypothesis that, at 30 days and 6 months after vascular surgery,
the perioperative administration of metoprolol reduces the incidence of cardiac compli-
cations deﬁned as cardiac death, nonfatal myocardial infarction (MI), congestive heart
failure (CHF), unstable angina, and dysrhythmias requiring treatment
Country: Canada
Setting: 3 tertiary care centres: General Campus, Hamilton Health Sciences; Victoria
Campus, London Health Sciences; and Kingston General Hospital between 1999 and
2002
Recruitment: all patients undergoing vascular surgery were screened for eligibility. Elec-
tive vascular surgical patients are evaluated by internists, cardiologists, or anaesthesiolo-
gists in preoperative clinics. Screening was also undertaken on the wards when applicable
Participants Inclusion criteria: patients with American Society of Anesthesiology class 3 or less and
undergoing abdominal aortic surgery and infrainguinal or axillofemoral revascularisation
Exclusion criteria: current or recent β-blocker use, current amiodarone use, airﬂow ob-
struction requiring treatment, history of CHF, history of atrioventricular block, previous
adverse drug reactions to β-blockers, and previous participation in the MaVS study
Gender: placebo group 184 M/66 F; metoprolol group 193 M/53 F
Age: placebo participants mean 65.9 ± 10.0 years; metoprolol participants mean 66.4 ±
10.0 years
Co-morbidities:
Prior MI: 30 placebo, 37 metoprolol
Angina: 25 placebo, 18 metoprolol
Diabetes mellitus on treatment: 37 placebo, 54 metoprolol
Permanent pacemaker: 1 placebo, 0 metoprolol
AAA subgroup: 116 placebo, 111 metoprolol
Interventions Treatment: metoprolol administered orally or intravenously. Participants weighing≥ 75
kg received metoprolol 100 mg; participants weighing between 40 and 75 kg received
metoprolol 50 mg; and participants weighing ≤ 40 kg received metoprolol 25 mg OR
intravenously at 1 mg/mL for 15 minutes. Intravenous (IV) treatment was converted to
oral as soon as oral intake was tolerated
Control: placebo administered orally as tablet or given intravenously as saline 0.2 mL/
kg (to a maximum of 15 mL), diluted with 20 mL of saline for 15 minutes
Duration: metoprolol or placebo given orally 2 hours preoperatively. Within 2 hours of
surgery, metoprolol or placebo were give intravenously or orally. IV drug administered
over 15 minutes every 6 hours. Oral administration was twice daily. Treatment lasted for
5 days or until hospital discharge, whichever occurred sooner
Co-interventions: short-acting vasoactive medications including phenylephrine,
ephedrine, nitroglycerine, and low-dose dopamine were allowed. Open-label β-blocker
use was strongly discouraged except when deemed absolutely necessary by the attending
physician. Circumstances for open-label use were generally for rapid heart rate control.
Intraoperatively, esmolol, if deemed absolutely necessary, was allowed
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Yang 2006 (Continued)
Outcomes Primary outcome: composite of cardiac complications at 30 days postoperation includ-
ing; cardiac death1, nonfatal MI2, CHF3 , unstable angina4 , and dysrhythmia requiring
treatment deﬁned as atrial ﬁbrillation or ventricular dysrhythmias5
1Cardiac death was deﬁned as either the ultimate cause of death traceable to an initiating
cardiac complication or death in which the cause was not clearly identiﬁable or was
insufﬁcient to account for the demise in a patient who was not expected to succumb at
the time of death
2Nonfatal MI within 3 postoperative deaths diagnosed if ≥ 1 of the following present:
chemical evidence of MI or new Q waves > 0.04 s on 2 contiguous leads. Beyond 3 days,
nonfatal MI was determined by attending physicians with supporting documentation of
hospital chart, troponins, and pre- and postoperative electrocardiograms
3Unstable angina diagnosed by attending physician when anginal symptoms necessitated
a change in medications, coronary revascularisation, or intensive care admission
4CHF was diagnosed clinically with the requisite radiographic evidence
5Dysrhythmia requiring treatment was deﬁned as one of the following: ventricular ﬁb-
rillation requiring counter shock, ventricular tachycardia requiring counter shock or
medication, or atrial ﬁbrillation > 15 minutes in duration requiring counter shock or
medication
Secondary outcomes:
• Study drug discontinuation due to bronchospasm, advanced heart blocks,
hypotension (systolic blood pressure < 90 mmHg) or bradycardia (50 beats/min).
• Reoperation or amputation.
• Intraoperative hypotension and bradycardia requiring treatment by the attending
anaesthesiologists.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was constructed
in blocks of 4 by the study statistician”
Allocation concealment (selection bias) Unclear risk Comment: Methods of concealment of al-
location are not stated. Insufﬁcient infor-
mation to permit judgement of low or high
risk of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients, investigators, and all
caretakers were blinded to the study ran-
domisation. Blinding of randomisationwas
maintained throughout clinical decisions
on reducing or discontinuing the study
medication”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All data were collected by the par-
ticipating centres and evaluated by the ad-
judication committee in a blinded fashion”
20Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic
aneurysm (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yang 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Completion of the study proto-
col was similar in the placebo (77.6%) and
treatment groups (75.2%). Discontinua-
tion of the study protocol was also simi-
lar in the placebo and treatment groups;
primary outcome event (30 and 25,respec-
tively); patient/family/physicianpreference
(27 and 14, respectively); open-label β-
blockers (24 and 14, respectively); patient
death (3 and 0, respectively), atrioventric-
ular block (2 and 3, respectively), bron-
chospasm (1 and 4, respectively); and other
reason (11 and 13, respectively).”
Comment: All missing data accounted for
and similarly balanced across the two treat-
ment groups. Low risk of attrition bias
Selective reporting (reporting bias) Low risk Quote: “Our results show that the RRR
achieved with perioperative metoprolol in
the vascular population is smaller than pre-
viously reported and is not signiﬁcant”
Comment: Authors commented on study
results in relation to expected outcomes
from other published reports. Further-
more, all of the primary and secondary pre-
speciﬁed outcomes were reported
Other bias Low risk The study appears to be free from other
sources of bias
Abbreviations: CHF: congestive heart failure; IV: intravenous; MI: myocardial infarction; RRR: relative risk reduction
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ashes 2013 The study did not report if there was a subgroup of participants with abdominal aortic aneurysm (AAA). We
attempted to contact the study author to see if these data were available but we could not make contact
Berwanger 2015 The study authors reported that 6.6% of participants had undergone vascular surgery but it did not report the
number, if any, with AAA. We attempted to contact the study author to see if these data were available but we
could not make contact
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(Continued)
Cesanek 2008 This study examined beta-blocker-related complications in patients undergoing vascular surgery. We contacted
the study authors for outcome data for AAA participants but they did not respond to communication
DECREASE Study The principal investigator of the DECREASE Study was dismissed for misconduct including failing to obtain
patient written informed consent and negligent data collection. A full copy of the report issued by the Erasmum
Medical Centre can be found here: Erasmus MC Follow-Up Committee 2012
Durazzo 2004 A subgroup of 56 participants underwent a AAA repair but speciﬁc outcome data for these participants were not
presented. Through personal communication, the study author conﬁrmed that these data were not available
Kouvelos 2011 The study did not report if there was a subgroup of participants with AAA. We attempted to contact the study
author to see if these data were available but we could not make contact
Kouvelos 2013 Of the 262 participants studied, 66% were taking antiplatelets, 19% anticoagulants, 23% calcium antagonists,
33% angiotensin-converting enzyme (ACE) inhibitors and 15% were taking angiotensin II receptors prior to
randomisation. Outcomes in this study could not be attributed to one speciﬁc drug and therefore we excluded
this study
Mackey 2006 Prospective study thatmeasured the incidence of perioperative myocardial ischaemic injury in high-risk vascular
surgery patients. It was not a randomised controlled trial and it did not administer drugs
Mangano 1996 The study did not report if there was a subgroup of participants with AAA. We attempted to contact the study
author to see if these were available but we could not make contact
NCT01225094 Intervention is curcumin, which is a natural health product
Neilipovitz 2012 Patients in this study were taking co-medications (angiotensin drugs, calcium channel blockers, beta blockers,
acetylsalicylic acid, clopidogrel) that we planned to assess in this review. Outcomes in this study could not be
attributed to one speciﬁc drug and therefore we excluded this study
POBBLE Trial Of the 103 participants included in this study, 38% underwent aortic repair. However the study did not present
outcome data for this subgroup. We attempted to retrieve these data but the study authors did not respond to
our communication
POISE Study Following personal communication, the study author conﬁrmed that data for the AAA participants were not
available
Qu 2014 The study did not report if there was a subgroup of participants with AAA. We attempted to contact the study
author to see if the data were available but we could not make contact
Schouten 2011 The study did not report if there was a subgroup of participants with AAA. We attempted to contact the study
author to see if the data were available but we could not make contact
Xia 2014 The study did not report if there was a subgroup of participants with AAA. We attempted to contact the study
author to see if the data were available but we could not make contact
Xia 2015 The study did not report if there was a subgroup of participants with AAA. We attempted to contact the study
author to see if the data were available but we could not make contact
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Abbreviations: AAA: abdominal aortic aneurysm; ACE: angiotensin-converting enzyme.
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D A T A A N D A N A L Y S E S
Comparison 1. Metoprolol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality, 30 days 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Cardiovascular death, 30 days 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 AAA-related death, 30 days 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Nonfatal cardiovascular event,
30 days
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 All-cause mortality, 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Cardiovascular death, 6 months 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Nonfatal cardiovascular event, 6
months
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Metoprolol versus placebo, Outcome 1 All-cause mortality, 30 days.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 1 All-cause mortality, 30 days
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 1/111 6/116 0.17 [ 0.02, 1.41 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
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Analysis 1.2. Comparison 1 Metoprolol versus placebo, Outcome 2 Cardiovascular death, 30 days.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 2 Cardiovascular death, 30 days
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 1/111 5/116 0.20 [ 0.02, 1.76 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
Analysis 1.3. Comparison 1 Metoprolol versus placebo, Outcome 3 AAA-related death, 30 days.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 3 AAA-related death, 30 days
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 1/111 1/116 1.05 [ 0.06, 16.92 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
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Analysis 1.4. Comparison 1 Metoprolol versus placebo, Outcome 4 Nonfatal cardiovascular event, 30 days.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 4 Nonfatal cardiovascular event, 30 days
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 12/111 9/116 1.44 [ 0.58, 3.57 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
Analysis 1.5. Comparison 1 Metoprolol versus placebo, Outcome 5 All-cause mortality, 6 months.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 5 All-cause mortality, 6 months
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 7/111 10/116 0.71 [ 0.26, 1.95 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
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Analysis 1.6. Comparison 1 Metoprolol versus placebo, Outcome 6 Cardiovascular death, 6 months.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 6 Cardiovascular death, 6 months
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 5/111 7/116 0.73 [ 0.23, 2.39 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
Analysis 1.7. Comparison 1 Metoprolol versus placebo, Outcome 7 Nonfatal cardiovascular event, 6 months.
Review: Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
Comparison: 1 Metoprolol versus placebo
Outcome: 7 Nonfatal cardiovascular event, 6 months
Study or subgroup Metoprolol Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yang 2006 13/111 10/116 1.41 [ 0.59, 3.35 ]
0.01 0.1 1 10 100
Favours metoprolol Favours placebo
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Aortic Aneurysm EXPLODE ALL
TREES
559
#2 ((aort* near3 (balloon* or dilat* or bulg* or rupture or expan*)
)):TI,AB,KY
438
#3 (aneury* near3 (abdominal or thoraco*)):TI,AB,KY 460
#4 AAA*:TI,AB,KY 693
#5 MESH DESCRIPTOR Vascular Surgical Procedures 523
#6 (vascular near3 surg*):TI,AB,KY 1408
#7 (infrarenal near3 surg*):TI,AB,KY 30
#8 (noncardiac near3 surg*):TI,AB,KY 175
#9 (non-cardiac near3 surg*):TI,AB,KY 122
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9
2969
#11 indobufen 81
#12 MESH DESCRIPTOR Platelet Aggregation Inhibitors EX-
PLODE ALL TREES
8224
#13 MESH DESCRIPTOR Phosphodiesterase Inhibitors EX-
PLODE ALL TREES
5416
#14 MESH DESCRIPTOR Tetrazoles 1790
#15 (antiplatelet* or anti-platelet* or antiaggreg* or anti-aggreg*)
:TI,AB,KY
2881
#16 (((platelet or thromboxane or thrombocyte or cyclooxyge-
nase or cyclo-oxygenase or phosphodiesterase or ﬁbrinogen or
PAR-1) near3 (antagonist or inhibitor))):TI,AB,KY
2178
#17 ((gp* or glycoprotein* or protease or P2Y12 or TXA2) near3
inhibit*):TI,AB,KY
2957
#18 thienopyridine:TI,AB,KY 230
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#19 (ticlopidine or Ticlid):TI,AB,KY 1665
#20 (clopidogrel or Plavix):TI,AB,KY 2634
#21 (Prasugrel or Efﬁent or Eﬁent or Prasita):TI,AB,KY 374
#22 (ticagrelor or AZD6140 or Brilinta):TI,AB,KY 278
#23 (elinogrel or PRT060128 or PRT-060128):TI,AB,KY 8
#24 (cangrelor or AR-C6993* or ARC6993*):TI,AB,KY 40
#25 (SCH530348 or SCH-530348):TI,AB,KY 16
#26 E5555:TI,AB,KY 5
#27 (terutroban or Triplion):TI,AB,KY 14
#28 (aspirin* or nitroaspirin or ASA):TI,AB,KY 16259
#29 (acetylsalicylic acid):TI,AB,KY 4352
#30 (acetyl salicylic acid*):TI,AB,KY 102
#31 (triﬂusal or disgren):TI,AB,KY 95
#32 (Cilostazol or Pletal or Pletaal):TI,AB,KY 436
#33 (dipyridamol* or Persantine):TI,AB,KY 1103
#34 (OPC-13013 or OPC13013):TI,AB,KY 5
#35 (picotamide or picotinamide):TI,AB,KY 41
#36 satigrel:TI,AB,KY 3
#37 vorapaxar:TI,AB,KY 63
#38 indobufen:TI,AB,KY 81
#39 MESHDESCRIPTOR Antihypertensive Agents EXPLODE
ALL TREES
22578
#40 MESH DESCRIPTOR Adrenergic beta-Antagonists EX-
PLODE ALL TREES
9426
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#41 MESHDESCRIPTORAngiotensin-Converting Enzyme In-
hibitors EXPLODE ALL TREES
5527
#42 MESH DESCRIPTOR Diuretics EXPLODE ALL TREES 5678
#43 MESH DESCRIPTOR Calcium Channel Blockers EX-
PLODE ALL TREES
7947
#44 (antihypertensi* or anti-hypertensi*):TI,AB,KY 13540
#45 (calcium near3 (antag* or block*)):TI,AB,KY 6255
#46 (amlodipin* or diltiazem or diltiazam or felodipin*):TI,AB,
KY
4362
#47 (nicardipin* or nifedipin* or nimodipin*):TI,AB,KY 4603
#48 (nisoldipin* or nitrendipin* or verapamil):TI,AB,KY 2736
#49 diureti*:TI,AB,KY 6368
#50 (angiotensin near3 inhibitor*):TI,AB,KY 5765
#51 (alacepril or altiopril or benazepril or captopril or ceronapril
or cilazapril or delapril or derapril ):TI,AB,KY
2804
#52 (enalapril or fosinopril or idapril or imidapril or lisinopril ):
TI,AB,KY
3648
#53 (moexipril or moveltipril or pentopril ):TI,AB,KY 38
#54 (perindopril or quinapril ):TI,AB,KY 1045
#55 (ramipril or spirapril or temocapril or trandolapril or zofeno-
pril):TI,AB,KY
1351
#56 (ACE next inhibitor*):TI,AB,KY 2565
#57 (adrenergic near3 (antagonist* or block*)):TI,AB,KY 8604
#58 (betablocker* or beta-blocker*):TI,AB,KY 4445
#59 (acebutolol or atenolol or Tenormin ):TI,AB,KY 3213
#60 (alprenolol or betaxolol or bisoprolol or bupranolol ):TI,AB,
KY
1153
#61 (carvedilol or Coreg or carteolol or celiprolol ):TI,AB,KY 1218
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#62 (esmolol or labetalol ):TI,AB,KY 1068
#63 (metoprolol or nadolol or nebivolol ):TI,AB,KY 3101
#64 (oxprenolol or penbutolol or pindolol ):TI,AB,KY 1239
#65 (practolol or propranolol or timolol):TI,AB,KY 6192
#66 *artan:TI,AB,KY 4870
#67 *sartan:TI,AB,KY 4854
#68 *dipine:TI,AB,KY 8436
#69 *olol:TI,AB,KY 13831
#70 *alol:TI,AB,KY 1150
#71 (bumetanide or ethacrynic acid or furosemide or torsemide):
TI,AB,KY
1967
#72 *thiazide:TI,AB,KY 4110
#73 epitizide:TI,AB,KY 2
#74 (indapamide or chlorthalidone or metolazone):TI,AB,KY 1055
#75 (amiloride or triamterene or spironolactone):TI,AB,KY 1768
#76 MESH DESCRIPTOR Anticholesteremic Agents EX-
PLODE ALL TREES
5458
#77 *statin:TI,AB,KY 11508
#78 meglutol:TI,AB,KY 2
#79 mevacor:TI,AB,KY 9
#80 pravachol:TI,AB,KY 5
#81 lescol:TI,AB,KY 47
#82 lipitor*:TI,AB,KY 23
#83 cholestyramine:TI,AB,KY 392
#84 (lipid next lowering):TI,AB,KY 2280
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#85 (cholesterol next lowering):TI,AB,KY 1182
#86 colestipol:TI,AB,KY 152
#87 gemﬁbrozil:TI,AB,KY 461
#88 cloﬁbrate:TI,AB,KY 314
#89 (nicotinic NEXT acid):TI,AB,KY 513
#90 ezetimibe:TI,AB,KY 698
#91 MESH DESCRIPTOR Fish Oils EXPLODE ALL TREES 2431
#92 MESH DESCRIPTOR Fatty Acids, Omega-3 EXPLODE
ALL TREES
2153
#93 (fatty next acid*):TI,AB,KY 10298
#94 (omega near2 acid*):TI,AB,KY 1840
#95 (*eicosapentanoic or docosahexanoic or docosapentanoic or
alpha-linolenic):TI,AB,KY
424
#96 (*eicosapentaen* or icosapentaenoic or docosahexaeno*):TI,
AB,KY
2165
#97 (ﬁsh near2 oil*):TI,AB,KY 1698
#98 (cod near2 oil):TI,AB,KY 58
#99 MESH DESCRIPTOR Antioxidants EXPLODE ALL
TREES
11258
#100 (antioxidant* or anti-oxidant*):TI,AB,KY 6756
#101 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or
#36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #
44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52
or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or
#61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #
69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77
or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or
#86 or #87 or #88 or #89 or #90 or #91 or #92 or #93 or #
94 or #95 or #96 or #97 or #98 or #99 or #100
114007
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#102 #10 and #101 522
#103 30/04/2013 TO 29/02/2016:DL 245401
#104 #102 AND #103 137
Appendix 2. Trials registries seaches
World Health Organization International Clinical Trials Registry Platform
27 new records found for abdominal aneurysm
ClinicalTrials.gov
109 new studies found for abdominal aneurysm
ISRCTN Register
10 new results for abdominal aneurysm
WH A T ’ S N E W
Date Event Description
14 October 2016 New citation required but conclusions have not
changed
Search rerun. No new studies included, eight new stud-
ies excluded. A ’Summary of ﬁndings’ table was added.
No change to conclusions
14 October 2016 New search has been performed Search rerun. No new studies included, eight new stud-
ies excluded
C O N T R I B U T I O N S O F A U T H O R S
LR drafted the protocol, selected studies for inclusion, assessed the quality of studies, performed data analyses, and wrote and updated
the review.
EA contributed to the protocol, selected studies for inclusion, assessed the quality of studies, and contributed to the text of the review
and review update.
GS contributed to the protocol and the text of the review and review update.
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D E C L A R A T I O N S O F I N T E R E S T
LR: none known
EA: none known
GS: none known
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Chief Scientist Ofﬁce, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Ofﬁce.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antihypertensive Agents [therapeutic use]; Aortic Aneurysm, Abdominal [∗complications; mortality]; Cardiovascular Agents
[∗therapeutic use]; Cardiovascular Diseases [mortality; ∗prevention & control]; Cause of Death; Metoprolol [∗therapeutic use]; Ran-
domized Controlled Trials as Topic; Risk Factors
MeSH check words
Humans
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